cycE1 Cancer Research Results

cycE1, cyclin E1(CCNE1): Click to Expand ⟱
Source:
Type: protein
Cyclin E1 is a protein that plays a crucial role in the regulation of the cell cycle, particularly during the G1 phase. It is a member of the cyclin family, which are proteins that bind to and activate cyclin-dependent kinases (CDKs). The cyclin E1-CDK2 complex is essential for the progression of cells from the G1 phase to the S phase, where DNA replication occurs.

In cancer, cyclin E1 has been found to be overexpressed in various types of tumors, including breast, ovarian, and lung cancers. This overexpression can lead to uncontrolled cell proliferation, a hallmark of cancer.
Scientific Papers found: Click to Expand⟱
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓,
IL1↓, IL-1β
TNF-α↓,
TGF-β↓, TGF-β1
NF-kB↓,
MIP2↓,
PGE2↓,
NO↓,
Hif1a↓,
KDR/FLK-1↓,
VEGF↓,
MMP2↓,
TIMP2↑,
ITGB1↑,
NCAM↑,
p‑ATM↑,
p‑ATR↑,
p‑CHK1↑,
p‑Chk2↑,
Wnt/(β-catenin)↓,
PI3K↓,
Akt↓,
ERK↓, ERK1/2
cMyc↓,
mTOR↓,
survivin↓,
cMET↓,
EGFR↓,
cycD1/CCND1↓,
cycE1↓,
CDK4/6↓,
p16↑,
p27↑,
Apoptosis↑,
TumAuto↑,
Ferroptosis↑,
oncosis↑,
TumCCA↑, G0/G1 into M phase, G0/G1 into S phase, G1 and G2/M
ROS↑, ovarian cancer cell line model, artesunate induced oxidative stress, DNA double-strand breaks (DSBs) and downregulation of RAD51 foci
DNAdam↑,
RAD51↓,
HR↓,

5653- BNL,    Borneol hinders the proliferation and induces apoptosis through the suppression of reactive oxygen species-mediated JAK1 and STAT-3 signaling in human prostate cancer cells
- in-vitro, Pca, PC3
ROS↑, BNL treatment with PC-3 cells induces cytotoxicity, increases ROS production, and causes apoptotic morphological changes in a concentration-dependent manner.
TumCP↓, BNL significantly reduced the expression of cell proliferation markers such as cyclin-D1, cyclin-D2 and cyclin-E1 (P<0.05) compared to untreated PC-3 control cells.
cycD1/CCND1↓,
cycE1↓,
Apoptosis↑, BNL treatment enhanced apoptosis rates by observed overexpression of Bcl-2-associated X protein (Bax), caspase-3
BAX↓,
Casp3↑,
Bcl-2↓, and down regulation B-cell leukemia/lymphoma 2 (Bcl-2) (P<0.05) expression in PC-3 cells.
IL6↓, Additionally, BNL reduced interleukin-6, JAK1, and STAT3 phosphorylation ((P<0.05) in PC-3 cells
JAK1↓,
STAT3↓, Thus, BNL may be a therapeutic agent against prostate cancer by blocking the STAT3 signaling axis.

1145- CHr,    Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways
- in-vitro, Cerv, HeLa
tumCV↓,
BAX↑,
BID↑,
BOK↑,
APAF1↑,
TNF-α↑,
FasL↑,
Fas↑,
FADD↑,
Casp3↑,
Casp7↑,
Casp8↑,
Casp9↑,
Mcl-1↓,
NAIP↓,
Bcl-2↓,
CDK4↓,
CycB/CCNB1↓,
cycD1/CCND1↓,
cycE1↓,
TRAIL↑,
p‑Akt↓,
Akt↓,
mTOR↓,
PDK1↓,
BAD↓,
GSK‐3β↑,
AMPK↑, AMPKa
p27↑,
P53↑,

459- CUR,    Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, RT4
Trop2↓,
Apoptosis↑,
cycE1↓,
p27↑,
TumCCA↑, curcumin induced G2/M cell cycle arrest

1613- EA,    Ellagitannins in Cancer Chemoprevention and Therapy
- Review, Var, NA
ROS↑, pomegranate ET inhibit pro-inflammatory pathways including, but not limited to, the NF-κB pathway, whose activation leads to immune reactions, inflammation, and the transcription of genes involved in cell survival, such as Bclx and inhibitors of apop
angioG↓, ET to inhibit angiogenesis
ChemoSen↑, ET could also be utilized to increase the sensitivity of tumor cells to standard chemotherapeutic drugs
BAX↑, induction of pro-apoptotic mediators (Bax and Bak), downregulation of Bcl-2 and Bcl-XL, and reduced expression of cyclin-dependent kinases 2, 4, 6, and cyclins D1, D2, and E
Bak↑,
Bcl-2↓,
Bcl-xL↓,
CDK2↓,
CDK4↓,
CDK6↓,
cycD1/CCND1↓,
cycE1↓,
TumCG↓, reduced LNCaP prostate cancer xenograft size, tumor vessel density, VEGF peptide levels and HIF-α expression after four weeks of treatment in severe combined immunodeficient mice
VEGF↓,
Hif1a↓,
eff↑, Oenothein B, a macrocyclic ET, and quercetin-3-O-glucuronide from Epilobium sp. herbs—used in traditional medicine to treat benign prostatic hyperplasia and prostatic adenoma—have been proven to strongly inhibit the proliferation of human prostate ca
COX2↓, pomegranate ET (i.e., punicalagin and ellagic acid) have been shown to suppress cyclooxygenase-2 (COX-2) protein expression in human colon cancer (HT-29) cells
TumCCA↑, pomegranate ET and their metabolites, i.e., urolithins A and C, inhibit HT-29 cells proliferation via G0/G1 and G2/M arrest
selectivity↑, interestingly, normal human breast epithelial cells (MCF-10A) were far less sensitive to the inhibitory effect of polyphenol-rich fractions.
Wnt/(β-catenin)↓, suppression of Wnt/β-catenin
*toxicity∅, LD50 of a standardized pomegranate fruit extract containing 30% punicalagin in Wistar rats was >5 g/kg b.w.,

1065- GA,    Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression
- vitro+vivo, Pca, NA
tumCV↓, GA decreased the cell viability of only PCa cell lines and not normal cells (contrary to another HDAC inhibitor, suberoylanilide hydroxamic acid) ****
MMP↓,
DNAdam↑,
HDAC1↓,
HDAC2↓,
PCNA↓,
cycD1/CCND1↓,
cycE1↓,
P21↑, up-regulating the expression of cell cycle arrest gene p21
TumVol↓, mice

4783- Lyco,    Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells
- in-vitro, GC, AGS - in-vitro, GC, SGC-7901 - in-vitro, Nor, GES-1
TumCG↓, Lycopene specifically suppressed cell growth monitored by Real-Time Cell Analyzer, induced cell cycle arrest and cell apoptosis detected by flow cytometry, and lowered mitochondrial membrane potentials assessed by JC-1 staining of AGS and SGC-7901 ce
TumCCA↑,
Apoptosis↑,
MMP↓,
selectivity↑, while did not affect those of GES-1 cells.
cycE1↓, Lycopene decreased the high expression levels of CCNE1 and increased the levels of TP53 in AGS and SGC-7901 cells without affecting those in GES-1 cells.
TP53↑,
*antiOx↑, Lycopene has a strong antioxidant property without pro-Vitamin A function


Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics ⓘ

BOK↑, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,   PDK1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 4,   BAD↓, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 1,   BID↑, 1,   Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 1,   p‑Chk2↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 1,   Mcl-1↓, 1,   NAIP↓, 1,   oncosis↑, 1,   p27↑, 3,   survivin↓, 1,   TRAIL↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 2,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 2,   HR↓, 1,   p16↑, 1,   P53↑, 1,   PCNA↓, 1,   RAD51↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE1↓, 7,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   ERK↓, 1,   GSK‐3β↑, 1,   HDAC1↓, 1,   HDAC2↓, 1,   mTOR↓, 2,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 2,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

CDK4/6↓, 1,   ITGB1↑, 1,   MMP2↓, 1,   NCAM↑, 1,   TGF-β↓, 1,   TIMP2↑, 1,   Trop2↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 2,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1↓, 1,   IL6↓, 2,   JAK1↓, 1,   MIP2↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   IL6↓, 2,   TP53↑, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 93

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Functional Outcomes ⓘ

toxicity∅, 1,  
Total Targets: 2

Scientific Paper Hit Count for: cycE1, cyclin E1(CCNE1)
1 Artemisinin
1 borneol
1 Chrysin
1 Curcumin
1 Ellagic acid
1 Gallic acid
1 Lycopene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:725  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page